Subscribe
gutzemberg
gutzemberg / iStockphoto.com
25 October 2017Americas

Sanofi takes on Mylan over diabetes injection

Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More on this story

Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.
Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
10 July 2014   French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?